Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Chemotherapy. The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Survival: 21.2 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: United States
City/State/Province: Houston, TX
Hospital: The University of Texas MD Anderson Cancer Center
Journal: Link
Date: 12/2013

This phase 3 study involved chemotherapy-naive, metastatic, castration-resistant prostate cancer patients who were divided into two separate treatment groups. Group A consisted of 762 patients with a median age of 69 years, while group B had 760 patients with a median age of 68 years.

Patients in group A were treated with the chemotherapy agent docetaxel and the biologic therapy agent dasatinib (a Src kinase inhibitor that interferes with cancer cell growth and tumor metastases).

Patients in group B were given docetaxel chemotherapy.

Treatment-related deaths due to febrile neutropenia, septic shock, cerebral hematoma (bleeding), and respiratory and cardio-respiratory failure were reported in group A. Grade 4 diarrhea and fatigue were also reported.

Treatment-related deaths due to infection, heart failure, and kidney failure were reported in group B. Grade 4 diarrhea and back pain were also reported.

The median overall survival times for groups A and B were 21.5 and 21.2 months, respectively.

This study was supported by Bristol-Myers Squibb (makers of dasatinib).

Correspondence: Dr. John C Araujo; email:

E-mail to a Friend Email Physician More Information